Search clinical trials for: TAS-102 oral solution

Total 1858 results

Taiho Oncology, Inc.

Completed

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Taiho Oncology, Inc.

Completed

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
The University of Hong Kong
Taiho Pharmaceutical Co., Ltd.

Recruiting

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Pancreas Cancer

Hong Kong
Taiho Oncology, Inc.

Approved for marketing

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

United States
Ente Ospedaliero Ospedali Galliera

Active, not recruiting

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Iron Overload | Neurodegenerative Disease

Italy
Rahul Parikh
Taiho Oncology, Inc.

Recruiting

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Bladder Cancer

United States
Taiho Oncology, Inc.

Completed

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Advanced Solid Tumors

United States, Czechia, Serbia
Taiho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TAS-102 in Solid Tumors

Advanced or Metastatic Solid Tumors

China
University of Florida
Taiho Oncology, Inc.

Terminated

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

Pancreatic Cancer

United States
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Sun Yat-sen University

Recruiting

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Pancreatic Neoplasms

China
National University Hospital, Singapore

Recruiting

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

Singapore
Taiho Oncology, Inc.

Completed

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Takeda

Completed

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants

Healthy Volunteers

United States
Zhejiang University

Recruiting

TAS-102 and Anlotinib in ≥3 Lines mGC

Gastric Cancer

China
University of Florida
Taiho Oncology, Inc.

Completed

TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

Squamous Cell Lung Carcinoma

United States
Taiho Oncology, Inc.

Completed

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Refractory Metastatic Gastric Cancer

France, United States, Spain, United Kingdom, Germany, Ireland, Japan, Belgium, Italy, Turkey, Belarus, Israel, Portugal, Russian Federation, Czechia, Poland, Canada, Romania
Taiho Oncology, Inc.

Completed

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE)

Colorectal Cancer

United States, Spain, United Kingdom, Australia, Sweden, Belgium, France, Ireland, Germany, Austria, Japan, Italy, Czechia
Takeda

Completed

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Healthy Volunteers

United States
Sun Yat-sen University

Recruiting

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Metastatic Colorectal Cancer

China
Fudan University

Recruiting

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | Refractory Colorectal Carcinoma

China
AIO-Studien-gGmbH
Bayer; Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest...

Completed

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy (REMETY)

Pretreated Metastatic Colorectal Cancer

Germany
Chengdu SciMount Pharmatech Co., Ltd.

Completed

A Phase 1 Study of SMP-100 in Normal Healthy Volunteers

Healthy Volunteers

Australia
Wakayama Medical University
Epidemiological and Clinical Research Information Network

Unknown

Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After Pancreaticoduodenectomy (JAPAN-PD)

Paralytic Ileus

Japan
Takeda

Completed

TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants

Healthy

United Kingdom
Aerie Pharmaceuticals

Completed

Ocular Hypotensive Efficacy of AR-102

Glaucoma

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Dry Eye Syndromes

United States
Takeda

Completed

A Study of TAK-105 in Healthy Adults

Healthy Volunteers

United States
Taiho Pharmaceutical Co., Ltd.

Recruiting

AB122 Platform Study

Gastric Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Alveolar Soft Part Sarcoma | Advanced or Metastatic Solid Tumor

Japan
Taiho Oncology, Inc.

Completed

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

Advanced Solid Tumors

United States
Taiho Pharmaceutical Co., Ltd.

Terminated

Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Debiopharm International SA

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Baxdrostat Bioavailability and Bioequivalence Study

Hypertension

United States
Chengdu SciMount Pharmatech Co., Ltd.

Completed

3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability

Healthy Volunteers

Australia
SRI International
Taiho Pharmaceutical Co., Ltd.

Completed

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

Breast Cancer

United States
Taiho Pharmaceutical Co., Ltd.

Terminated

Phase II Study of TAS-106 to Treat Head and Neck Cancer

Head and Neck Cancer

United States, Hong Kong, Singapore, Taiwan
Yale University

Completed

TAS-OX for Refractory Metastatic Colon Cancer

Colorectal Neoplasms

United States
Aldeyra Therapeutics, Inc.
ORA, Inc.

Completed

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Takeda

Active, not recruiting

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

Solid Tumors

Japan
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Metastatic Colorectal Cancer

Russian Federation
Institut für Klinische Krebsforschung IKF GmbH...
Eli Lilly and Company; Trium Analysis Online GmbH

Active, not recruiting

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS)

Colorectal Cancer

Germany
Taiho Pharmaceutical Co., Ltd.

Completed

Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia (TERRA)

Colorectal Cancer

Korea, Republic of, China, Thailand
Jazz Pharmaceuticals
Evidilya S.r.l.

Not yet recruiting

Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY (EpiTALY)

Dravet Syndrome | Lennox Gastaut Syndrome

Italy
Aldeyra Therapeutics, Inc.

Completed

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Non-infectious Anterior Uveitis

United States
Ocera Therapeutics, Inc.

Completed

OCR002-SP103 - Oral Immediate Release Study

Cirrhosis

United States
Verrica Pharmaceuticals Inc.
BioClinica, Inc.; Paidion Research, Inc.; Instat Consulting, Inc.; ALMAC Clinical...

Completed

Cantharidin and Occlusion in Verruca Epithelium (COVE-1)

Skin Diseases | Virus Diseases | DNA Virus Infections | Skin Diseases, Infectious | Warts | Papillomavirus Infections | Skin Diseases, Viral | Tumor Virus Infections | Common Wart | Verruca Vulgaris | Warts Hand | Verruca

United States
AlzProtect SAS

Active, not recruiting

A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP

Progressive Supranuclear Palsy

France
Crinetics Pharmaceuticals Inc.

Completed

Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers

Healthy Volunteers

United States
Crinetics Pharmaceuticals Inc.

Completed

A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers

Healthy Volunteers

Australia

Search clinical trials for: TAS-102 oral solution

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations